Tissue Regenix secures HTA license to import CellRight products
Regenerative medical devices group Tissue Regenix has been granted a Human Tissue Authority (HTA) licence to import and distribute its portfolio of human tissue derived products from the US for use in the UK market.
The HTA license will initially be used to import the CellRight ‘BioRinse’ portfolio of osteoinductive bone products from a manufacturing facility in San Antonio, Texas into the UK.
The group acquired CellRight in August last year, securing access to the US biotech’s osteoinductive and wound care scaffolds “that enhance healing opportunities of defects created by trauma and disease”.
Read more: http://www.pharmatimes.com/news/tissue_regenix_secures_hta_license_to_import_cellright_products_1241791
The HTA license will initially be used to import the CellRight ‘BioRinse’ portfolio of osteoinductive bone products from a manufacturing facility in San Antonio, Texas into the UK.
The group acquired CellRight in August last year, securing access to the US biotech’s osteoinductive and wound care scaffolds “that enhance healing opportunities of defects created by trauma and disease”.
Read more: http://www.pharmatimes.com/news/tissue_regenix_secures_hta_license_to_import_cellright_products_1241791